No Job Openings Found For Aastrom Biosciences
Jobs by
Latest $100K+ Job Openings in Michigan
| City | Title | Compensation |
|---|---|---|
| Detroit |
Senior Account Executive (Detroit) PAETEC is hiring a Senior Account Executive for our Detroit Sales Office!You can be part of the most dynamic network solutions provider in t... |
100K |
| Grand Rapids |
Leadership Development Specialist Title: Leadership Development SpecialistLocation: Meijer Headquarters - Grand Rapids, MI The individual selected for this positi... |
$100K |
| Grand Rapids |
Financial Advisor - Training Program FINANCIAL ADVISOR / PERSONAL WEALTH MANAGERThis is an exclusive executive position with an elite wealth management firm that only hires successfu... |
$120K+ |
| Kalamazoo |
Sales - Financial Planning - Women & Minority Markets We represent a global brand seeking proven sales professionals to join our team. Now is your chance to start a new sales related career in... |
$125K+ |
| Warren |
Director - Legal Operations and Centralized Services The Director of Legal Operations and Centralized Services is responsible for leading Asset Acceptance’s Legal Operations team and managing... |
$100K |
 | ||
Interview Tip
-
Appointments And Advancements [BioWorld Today](20 Nov 2009 00:01:00 EST)Aastrom Biosciences Inc., of Ann Arbor, Mich., elected Harold C. Urschel to its board. Advaxis Inc., of North Brunswick, N.J., appointed Christopher Duignan senior vice president of finance. Affymax Inc., of Palo Alto, Calif., appointed Hollings C. Renton chairman, effective Dec. 1.
-
Appointments And Advancements [BioWorld Today](16 Nov 2009 00:01:00 EST)Aastrom Biosciences Inc., of Ann Arbor, Mich., elected Harold C. Urschel to its board. Advaxis Inc., of North Brunswick, N.J., appointed Christopher Duignan senior vice president of finance. Affymax Inc., of Palo Alto, Calif., appointed Hollings C. Renton chairman, effective Dec. 1, 2009.
-
Aastrom to commence second Phase II study for treatment of severe chronic heart failure(11 Nov 2009 06:21:00 EST)11 November 2009 - US-based regenerative medicine company Aastrom Biosciences Inc said yesterday it will start its second Phase II clinical trial for the treatment of dilated cardiomyopathy after a positive 30-day review of the company's Investigational New Drug submission by the US Food & Drug Administration.
